ELI LILLY AND COMPANY Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ELI LILLY AND COMPANY (LLY) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $5.58 billion for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-02-23
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was $2.12B, a 41.53% increase year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was $1.21B, a 3.63% decline year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was $1.41B, a 6.39% increase year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was $1.46B, a 159.58% increase year-over-year.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $5.58B, a 9.88% decline from fiscal 2020.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $6.19B, a 33.55% increase from fiscal 2019.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was $4.64B, a 47.21% increase from fiscal 2018.
- ELI LILLY AND COMPANY income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was $3.15B.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2021-12-31 | $5.58B 10-K · filed 2022-02-23 | |||
| 2020-12-31 | $2.12B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $3.33B derived: sum of 2 quarters · filed 2022-02-23 | $4.74B derived: sum of 3 quarters · filed 2022-02-23 | $6.19B 10-K · filed 2022-02-23 |
| 2020-09-30 | $1.21B 10-Q · filed 2020-10-28 | $2.62B derived: sum of 2 quarters · filed 2020-10-28 | $4.08B 10-Q · filed 2020-10-28 | $5.57B derived: sum of 4 quarters · filed 2020-10-28 |
| 2020-06-30 | $1.41B 10-Q · filed 2020-07-31 | $2.87B 10-Q · filed 2020-07-31 | $4.36B derived: sum of 3 quarters · filed 2020-07-31 | $5.62B derived: sum of 4 quarters · filed 2020-10-28 |
| 2020-03-31 | $1.46B 10-Q · filed 2020-05-01 | $2.95B derived: sum of 2 quarters · filed 2020-05-01 | $4.21B derived: sum of 3 quarters · filed 2020-10-28 | $5.53B derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-12-31 | $1.50B 10-K · filed 2020-02-19 | $2.75B derived: sum of 2 quarters · filed 2020-10-28 | $4.08B derived: sum of 3 quarters · filed 2020-10-28 | $4.64B 10-K · filed 2022-02-23 |
| 2019-09-30 | $1.25B 10-Q · filed 2020-10-28 | $2.58B derived: sum of 2 quarters · filed 2020-10-28 | $3.14B 10-Q · filed 2020-10-28 | $4.26B derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $1.33B 10-Q · filed 2020-07-31 | $1.89B 10-Q · filed 2020-07-31 | $3.01B derived: sum of 3 quarters · filed 2020-07-31 | $4.10B derived: sum of 4 quarters · filed 2020-07-31 |
| 2019-03-31 | $561.10M 10-Q · filed 2020-05-01 | $1.68B derived: sum of 2 quarters · filed 2020-05-01 | $2.78B derived: sum of 3 quarters · filed 2020-05-01 | $2.54B derived: sum of 4 quarters · filed 2020-05-01 |
| 2018-12-31 | $1.12B 10-K · filed 2020-02-19 | $2.21B derived: sum of 2 quarters · filed 2020-02-19 | $1.98B derived: sum of 3 quarters · filed 2020-02-19 | $3.15B 10-K · filed 2021-02-17 |
| 2018-09-30 | $1.09B 10-K · filed 2020-02-19 | $862.00M derived: sum of 2 quarters · filed 2020-02-19 | $2.03B 10-Q · filed 2019-10-25 | $478.70M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | -$231.60M 10-K · filed 2020-02-19 | $935.60M 10-Q · filed 2019-08-02 | -$614.90M derived: sum of 3 quarters · filed 2020-02-19 | -$70.80M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $1.17B 10-K · filed 2020-02-19 | -$383.30M derived: sum of 2 quarters · filed 2020-02-19 | $160.80M derived: sum of 3 quarters · filed 2020-02-19 | $1.17B derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | -$1.55B 8-K · filed 2019-10-24 | -$1.01B derived: sum of 2 quarters · filed 2019-10-24 | -$1.30M derived: sum of 3 quarters · filed 2019-10-24 | -$86.40M 10-K · filed 2020-02-19 |
| 2017-09-30 | $544.10M 8-K · filed 2019-10-24 | $1.55B derived: sum of 2 quarters · filed 2019-10-24 | $1.46B derived: sum of 3 quarters · filed 2019-10-24 | |
| 2017-06-30 | $1.01B 8-K · filed 2019-10-24 | $920.00M derived: sum of 2 quarters · filed 2019-10-24 | ||
| 2017-03-31 | -$85.10M 8-K · filed 2019-10-24 | |||
| 2016-12-31 | $2.72B 8-K · filed 2019-10-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |